-
Mashup Score: 0U.S. FDA declines to approve Eli Lilly's drug to treat eczema - 7 month(s) ago
The U.S. Food and Drug Administration (FDA) has declined to approve Eli Lilly’s drug to treat a type of skin disease due to certain findings during an inspection of a contract manufacturer, the drugmaker said on Monday.
Source: www.reuters.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Protecting children from poor air quality - 7 month(s) ago
3 in 4 parents are concerned about the impact of air quality problems on their child’s health. 2 in 3 parents report poor or unhealthy air quality in their area, most often related to wildfires. Among parents reporting poor air quality in their area, 1 in 5 believe it affected their child’s health.
Source: mottpoll.orgCategories: Healthcare Professionals, Latest HeadlinesTweet-
Protecting children from poor air quality https://t.co/LFaCAZ5uR6 via @csmottpoll
-
-
Mashup Score: 2FDA Reviewers Say OTC Decongestant Doesn't Work - 8 month(s) ago
But they acknowledge that taking the only shelf-accessible product off the market raises issues
Source: www.medpagetoday.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
FDA Reviewers Say OTC Decongestant Doesn't Work https://t.co/3FZCIcrr5h
-
-
Mashup Score: 0
Nestlé announced Monday the divestment of its peanut allergy treatment business Palforzia (peanut allergen powder-dnfp) to Stallergenes Greer for an undisclosed sum. Nestlé kicked off…
Source: ml.firstwordpharma.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
https://t.co/4r8LGwAPQ4
-
-
Mashup Score: 0AstraZeneca Halts Phase II Asthma Trial Due to Safety Findings in Toxicology Study | BioSpace - 10 month(s) ago
Pieris Pharmaceuticals announced partner AstraZeneca’s decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor, based on a non-clinical toxicology study.
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet-
https://t.co/Ag7jk8qpeb
-
-
Mashup Score: 0FirstWord - 11 month(s) agoSource: firstwordpharma.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Blueprint's Ayvakit gets FDA nod for indolent systemic mastocytosis https://t.co/zJFf3Mff4x via @fwpharma
-
-
Mashup Score: 0
For patients who have undiagnosed cancer, a months-long delay due to new prior authorization requirements for colonoscopies could be disastrous.
Source: STATCategories: Healthcare Professionals, Latest HeadlinesTweet-
‘Stunning’ change to United’s colonoscopy coverage roils physicians and patients https://t.co/ov3M1AA9Mx via @statnews. Just when you think it can’t get any crazier.
-
-
Mashup Score: 0Dupilumab not linked to short-term cancer development in patients with atopic dermatitis - 1 year(s) ago
Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.“A common question that comes up is whether the biologics that we routinely use in clinical practice, such as dupilumab, are safe in this
Source: www.healio.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Dupilumab not linked to short-term cancer development in patients with atopic dermatitis https://t.co/Pp8CtAcLkE
-
-
Mashup Score: 1
The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.
Source: www.healio.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
FDA approves leniolisib for activated phosphoinositide 3-kinase delta syndrome https://t.co/3zNCmqrw8X
-
-
Mashup Score: 1FirstWord - 1 year(s) agoSource: firstwordpharma.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Sanofi, Regeneron's Dupixent tops expectations in first pivotal COPD study https://t.co/NfTeh2j5gw via @fwpharma
-
U.S. FDA declines to approve Eli Lilly's drug to treat eczema https://t.co/UC0THbYSW4